NeoGenomics, Inc. Hits New 52-Week High at USD 14.48

NeoGenomics, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 14.48 on June 29, 2026. This achievement marks a notable increase from its 52-week low of USD 4.72, reflecting a year-over-year performance of 6.98%. With a market capitalization of USD 933 million, NeoGenomics operates in a competitive industry characterized by rapid advancements and evolving market dynamics. The company's financial metrics indicate a debt-to-equity ratio of 0.22, suggesting a relatively low level of debt compared to equity. However, it is important to note that the company is currently loss-making, as indicated by the absence of a price-to-earnings ratio. The price-to-book ratio stands at 1.12, which may provide insights into the company's valuation relative to its assets. As NeoGenomics continues to navigate the complexities of the biotechnology landscape, this recent price milestone underscores its current market position and performance.